Cargando…
Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
BACKGROUND: Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck ca...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286492/ https://www.ncbi.nlm.nih.gov/pubmed/37344761 http://dx.doi.org/10.1186/s12885-023-11062-3 |
_version_ | 1785061761962999808 |
---|---|
author | Yu, Brian Ma, Sung Jun Khan, Michael Gill, Jasmin Iovoli, Austin Fekrmandi, Fatemeh Farrugia, Mark K. Wooten, Kimberly Gupta, Vishal McSpadden, Ryan Kuriakose, Moni A. Markiewicz, Michael R. Al-Afif, Ayham Hicks, Wesley L. Seshadri, Mukund Ray, Andrew D. Repasky, Elizabeth A. Singh, Anurag K. |
author_facet | Yu, Brian Ma, Sung Jun Khan, Michael Gill, Jasmin Iovoli, Austin Fekrmandi, Fatemeh Farrugia, Mark K. Wooten, Kimberly Gupta, Vishal McSpadden, Ryan Kuriakose, Moni A. Markiewicz, Michael R. Al-Afif, Ayham Hicks, Wesley L. Seshadri, Mukund Ray, Andrew D. Repasky, Elizabeth A. Singh, Anurag K. |
author_sort | Yu, Brian |
collection | PubMed |
description | BACKGROUND: Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck cancer was unclear in several meta-analyses, and there is a paucity of literature including patients in North America. We performed an observational cohort study to evaluate the association of LMR with survival outcomes in North American patients with head and neck cancer. METHODS: A single-institution, retrospective database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation from June 2007 to April 2021 at the Roswell Park Comprehensive Cancer Center. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The association of LMR with OS and CSS was examined using nonlinear Cox proportional hazard model using restricted cubic splines (RCS). Cox multivariable analysis (MVA) and Kaplan–Meier method were used to analyze OS and CSS. Pre-radiation LMR was then stratified into high and low based on its median value. Propensity scored matching was used to reduce the selection bias. RESULTS: A total of 476 patients met our criteria. Median follow up was 45.3 months (interquartile range 22.8–74.0). The nonlinear Cox regression model showed that low LMR was associated with worse OS and CSS in a continuous fashion without plateau for both OS and CSS. On Cox MVA, higher LMR as a continuous variable was associated with improved OS (adjusted hazard ratio [aHR] 0,90, 95% confidence interval [CI] 0.82–0.99, p = 0.03) and CSS (aHR 0.83, 95% CI 0.72–0.95, p = 0.009). The median value of LMR was 3.8. After propensity score matching, a total of 186 pairs were matched. Lower LMR than 3.8 remained to be associated with worse OS (HR 1.59, 95% CI 1.12–2.26, p = 0.009) and CSS (HR 1.68, 95% CI 1.08–2.63, p = 0.02). CONCLUSION: Low LMR, both as a continuous variable and dichotomized variable, was associated with worse OS and CSS. Further studies would be warranted to evaluate the role of such prognostic marker to tailor interventions. |
format | Online Article Text |
id | pubmed-10286492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102864922023-06-23 Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation Yu, Brian Ma, Sung Jun Khan, Michael Gill, Jasmin Iovoli, Austin Fekrmandi, Fatemeh Farrugia, Mark K. Wooten, Kimberly Gupta, Vishal McSpadden, Ryan Kuriakose, Moni A. Markiewicz, Michael R. Al-Afif, Ayham Hicks, Wesley L. Seshadri, Mukund Ray, Andrew D. Repasky, Elizabeth A. Singh, Anurag K. BMC Cancer Research BACKGROUND: Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck cancer was unclear in several meta-analyses, and there is a paucity of literature including patients in North America. We performed an observational cohort study to evaluate the association of LMR with survival outcomes in North American patients with head and neck cancer. METHODS: A single-institution, retrospective database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation from June 2007 to April 2021 at the Roswell Park Comprehensive Cancer Center. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The association of LMR with OS and CSS was examined using nonlinear Cox proportional hazard model using restricted cubic splines (RCS). Cox multivariable analysis (MVA) and Kaplan–Meier method were used to analyze OS and CSS. Pre-radiation LMR was then stratified into high and low based on its median value. Propensity scored matching was used to reduce the selection bias. RESULTS: A total of 476 patients met our criteria. Median follow up was 45.3 months (interquartile range 22.8–74.0). The nonlinear Cox regression model showed that low LMR was associated with worse OS and CSS in a continuous fashion without plateau for both OS and CSS. On Cox MVA, higher LMR as a continuous variable was associated with improved OS (adjusted hazard ratio [aHR] 0,90, 95% confidence interval [CI] 0.82–0.99, p = 0.03) and CSS (aHR 0.83, 95% CI 0.72–0.95, p = 0.009). The median value of LMR was 3.8. After propensity score matching, a total of 186 pairs were matched. Lower LMR than 3.8 remained to be associated with worse OS (HR 1.59, 95% CI 1.12–2.26, p = 0.009) and CSS (HR 1.68, 95% CI 1.08–2.63, p = 0.02). CONCLUSION: Low LMR, both as a continuous variable and dichotomized variable, was associated with worse OS and CSS. Further studies would be warranted to evaluate the role of such prognostic marker to tailor interventions. BioMed Central 2023-06-21 /pmc/articles/PMC10286492/ /pubmed/37344761 http://dx.doi.org/10.1186/s12885-023-11062-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yu, Brian Ma, Sung Jun Khan, Michael Gill, Jasmin Iovoli, Austin Fekrmandi, Fatemeh Farrugia, Mark K. Wooten, Kimberly Gupta, Vishal McSpadden, Ryan Kuriakose, Moni A. Markiewicz, Michael R. Al-Afif, Ayham Hicks, Wesley L. Seshadri, Mukund Ray, Andrew D. Repasky, Elizabeth A. Singh, Anurag K. Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
title | Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
title_full | Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
title_fullStr | Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
title_full_unstemmed | Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
title_short | Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
title_sort | association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286492/ https://www.ncbi.nlm.nih.gov/pubmed/37344761 http://dx.doi.org/10.1186/s12885-023-11062-3 |
work_keys_str_mv | AT yubrian associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT masungjun associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT khanmichael associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT gilljasmin associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT iovoliaustin associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT fekrmandifatemeh associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT farrugiamarkk associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT wootenkimberly associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT guptavishal associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT mcspaddenryan associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT kuriakosemonia associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT markiewiczmichaelr associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT alafifayham associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT hickswesleyl associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT seshadrimukund associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT rayandrewd associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT repaskyelizabetha associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation AT singhanuragk associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation |